体重与伏立康唑稳态血药谷浓度的相关性分析

目的分析临床患者体重与伏立康唑稳态血药谷浓度的相关性。方法采用HPLC 法对57 例使用伏立康唑静脉滴注治疗的患者进行稳态血药谷浓度测定, 分析其与体重的相关性。结果在使用200 mg、q12 h 维持剂量的伏立康唑时,随体重增加,伏立康唑稳态血药谷浓度呈降低趋势;70 －80 kg 体重患者中采用300 mg、q12 h 的维持剂量患者的稳态谷浓度明显高于采用200 mg、q12 h 维持剂量的患者（P 〈0. 01）。结论体重与伏立康唑稳态血药谷浓度有一定相关性。

Correlational Analysis of Weight and Voriconazole Steady-State Plasma Trough Concentration

Objective To investigate the association between weight and steady-state plasma trough concentration of voriconazole in clinical patient. Methods HPLC method was set up to measure steady-state plasma trough concentrations of voriconazole in 57 patients with intravenous drip, to analyze the relevance to body weight of the patients. Results Under the maintenance dose regimen of 200 mg q12 h, with the increase of body weight, steady-state plasma trough concentration of voriconazole was decreasing. Two maintenance dose regimens were compared in patients with 70 - 80 kg body weight, the steady-state trough concentrations of 300 mg q12 h maintenance dose group were significantly higher than those of 200 mg q12 h maintenance dose group （P 〈0.01 ）. Conclusion There might be a relationship between weight and steady-state plasma trough concentration of voriconazole.